<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02179944</url>
  </required_header>
  <id_info>
    <org_study_id>2014p000824</org_study_id>
    <secondary_id>SFPRF14-20</secondary_id>
    <nct_id>NCT02179944</nct_id>
  </id_info>
  <brief_title>Human Chorionic Gonadotropin (hCG) Trend After Medication Abortion</brief_title>
  <official_title>Human Chorionic Gonadotropin (hCG) Trend After Medication Abortion: A Prospective Physiologic Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Planned Parenthood League of Massachusetts</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Planned Parenthood League of Massachusetts</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project will be a prospective physiologic study. We will closely follow 60 medication&#xD;
      abortion patients with serial repeat serum hCG and urine semi-quantitative hCG testing. We&#xD;
      plan to recruit patients from two gestational age strata: ≤ 49 days and &gt; 49 days.&#xD;
&#xD;
      Study Objectives:&#xD;
&#xD;
        1. To create a nomogram describing the change in serum hCG values in the first five days&#xD;
           immediately following medication abortion with mifepristone and misoprostol.&#xD;
           Specifically, we will describe the percent serum hCG decline from Day 1 (day of&#xD;
           mifepristone) to Day 3 (day after misoprostol), from Day 1 to Day 5, and from Day 1 to&#xD;
           Day 7-10.&#xD;
&#xD;
        2. To explore whether there is a significant difference in the rate of hCG decline based on&#xD;
           initial gestational age determined by ultrasound and initial serum hCG.&#xD;
&#xD;
        3. To describe the correlation between semi-quantitative urine hCG test results and serum&#xD;
           hCG values to determine how soon after initiating medication abortion the urine test can&#xD;
           detect completed abortion.&#xD;
&#xD;
      We hypothesize that among successful medication abortions, there will be a predictable trend&#xD;
      with at least a 50% drop by Day 3 and 80% drop by Day 5.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percent serum hCG decline from Day 1 to Day 3, from Day 1 to Day 5, and from Day 1 to Day 7-10</measure>
    <time_frame>10 days from misoprostol administration</time_frame>
    <description>blood sample collection for hCG testing on Day 3, Day 5 and Day 7-10 (Day 1 is day of mifepristone administration)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>difference in rate of hCG decline based on initial gestational age</measure>
    <time_frame>10 days after misoprostol administration</time_frame>
    <description>blood sample collection for hCG testing on Day 3, Day 5 and Day 7-10 (Day 1 is day of mifepristone administration)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>how soon after initiating medication abortion a semi-quantitative urine pregnancy test can detect completed abortion</measure>
    <time_frame>10 days</time_frame>
    <description>urine sample collection for hCG testing using semi-quantitative urine pregnancy test on Day 1, Day 3, Day 5 and Day 7-10 (Day 1 is day of mifepristone administration)</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">66</enrollment>
  <condition>Undesired Pregnancy</condition>
  <arm_group>
    <arm_group_label>Participants</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        adult patients seeking medication abortion from an outpatient health center&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Desire for medication abortion for pregnancy termination AND&#xD;
&#xD;
          -  Pregnancy confirmed by ultrasound and gestational age ≤ 63 days based on transvaginal&#xD;
             ultrasound (TVUS) OR&#xD;
&#xD;
          -  Positive high-sensitivity urine hCG and intrauterine pregnancy (IUP) not confirmed on&#xD;
             TVUS&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Ineligibility for medication abortion at Planned Parenthood League of Massachusetts&#xD;
             (PPLM) based on current PPLM clinical guidelines&#xD;
&#xD;
          -  Initiation of medication abortion on Wednesday or Friday&#xD;
&#xD;
          -  Failed pregnancy defined as:&#xD;
&#xD;
               -  Crown-rump length ≥ 7mm and no heartbeat&#xD;
&#xD;
               -  Mean sac diameter ≥ 25mm and no embryo&#xD;
&#xD;
          -  Reasonable clinical suspicion for ectopic or molar pregnancy such as abnormal or&#xD;
             concerning ultrasound findings&#xD;
&#xD;
          -  Multiple gestation&#xD;
&#xD;
          -  Age less than 18 years&#xD;
&#xD;
          -  Prior participation in this study&#xD;
&#xD;
          -  Anticipated inability to present for scheduled follow-up visits&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Principal Investigator, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>PPLM</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Planned Parenthood</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <study_first_submitted>June 30, 2014</study_first_submitted>
  <study_first_submitted_qc>June 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2014</study_first_posted>
  <last_update_submitted>August 14, 2015</last_update_submitted>
  <last_update_submitted_qc>August 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>medication abortion</keyword>
  <keyword>serum hCG</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

